ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

NameABBVON

RankNo.3150

Market Cap$0.00

Fully Diluted Market Cap$0.00

Market Share%

Trading Vol/Market Cap (24H)439,940.04%

Circulation Supply215.74112722

Max Supply0

Total Supply215.74112722

Circulation Rate%

Issue Date--

The price at which the asset was first issued--

All-Time High237.64005999136555,2026-03-05

Lowest Price203.8145967524712,2026-03-24

Public BlockchainETH

IntroductionAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Sector

Social Media

• Official Website
• Block Explorer

etfindex:mc_etfindex_sourceDisclaimer: Data provided by cmc and should not be considered as investment advice.